Compare Eaton Corporation plc (ETN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Sanofi SA — how do they compare? Eaton Corporation plc trades at $429.92 (market cap $164.88B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Eaton Corporation plc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Sanofi SA for 94 Days on average.
| ETN | SNY | |
|---|---|---|
Market Cap | $164.88B | $95.18B |
Volume | 2,535,086 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $459.96 | $52.34 |
52-Week Low | $315.82 | $39.51 |
Typical Hold Time | 31 Days | 94 Days |
Enterprise Value | $185.51B | $114.48B |
Dividend Yield | 1.04% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $424.64, down 1.55% today, with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. ETN maintains robust profitability with 12.75% net income margin and 19.71% ROE, supported by strategic acquisitions in data center and aerospace markets. Recent news highlights growing investor attention and positive analyst coverage.
ETN presents a compelling growth story driven by data center demand and grid modernization, with 70% analyst buy ratings and a $502.38 consensus price target suggesting 18% upside. However, elevated valuation multiples (P/E 43.23) and bearish technical indicators warrant caution. Key risks include execution of acquisition strategy and competitive pressures in the electronics manufacturing sector.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
